Infection ViralNCT06286657
Xanthohumol and Viral Infections (XL)
A study testing Xanthohumol in people with Infection Viral, run by University of Vienna at 1 site in Austria.
Trial summary
The aim of the present study is to determine if a regular oral supplementation of xanthohumol attenuate the severity of symptoms and duration of´viral infections. Read more about this study
- Who is it for?
- Ages 18 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Infection Viral
- What is being tested?
- Xanthohumol
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- 1 siteAustria
- Study dates
- 1 Aug 2023to 30 Dec 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- healthy
- BMI >18 kg/m² or < 28kg/m²
Who cannot join
- food intolerances
- food allergies
- chronic inflammatory diseases
- metabolic diseases
- viral or bacterial infections within the last 3 weeks of inclusion
- intake of immunosuppressive medication
- severe acute respiratory syndrome coronavirus type 2-infection in the last 4 months
- influenza infection in the "current" flu season
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Austria1 site, 1 recruiting
- Recruiting
University of Vienna
Vienna, 1090
Ina Bergheim, Prof. Dr., +43-1-4277-54981, ina.bergheim@univie.ac.at
About this study
Official title: Xanthohumol in the Prevention of Virus-mediated Upper Respiratory Tract Infections in Humans
The aim of the present study is to determine if a regular oral supplementation of xanthohumol attenuate the severity of symptoms and duration of´viral infections.
Read the detailed description
In this placebo-controlled study, blood is taken on the first day of the study, followed by a 90-day intervention with xanthohumol or a placebo, which is taken twice daily. Blood samples will be taken on day 0, day 45 and day 90. Should the study participants develop a respiratory infection during the study, they will be asked to perform a self-test.
- Conditions
- Infection Viral
- Being tested
- Xanthohumol, Placebo
- Medical subject headings
- Virus Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
XanthohumolDietary supplement
Participants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days
PlaceboDietary supplement
Participants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | Participants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days Receives: Dietary Supplement: Xanthohumol |
| Placebo | Experimental | Participants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in severity and duration of viral infections
Changes in score of Wisconsin Upper Respiratory Symptom Survey
Measured: 90 days
Secondary outcomes (2)
Changes in blood lipid levels
Changes in triglyceride levels (mg/dl) and cholesterol levels (mg/dl)
Measured: 90 days
Changes in cognitive skills
Assessment of cognitive processes using stroop test
Measured: 90 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Feb 2024
- Study start1 Aug 2023
- Primary completion31 Oct 2025 (estimated)
- Study completion30 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Infection ViralStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Vienna
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Prof. Dr. Ina Bergheim, University of Vienna
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06286657
- Sponsor's protocol ID
- UVienna23a
- Status last verified
- Apr 2025
- First submitted
- 17 Jan 2024
- Last updated
- 15 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Xanthohumol in the Prevention of Virus-mediated Upper Respiratory Tract Infections in Humans
- ClinicalTrials.gov ID
- NCT06286657
- Acronym / sponsor ID
- UVienna23a
- Conditions
- Infection Viral
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University of ViennaUniversity, hospital or other
- Study start
- 1 Aug 2023 (actual)
- Primary completion
- 31 Oct 2025 (estimated)
- Study completion
- 30 Dec 2025 (estimated)
- First posted
- 29 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the present study is to determine if a regular oral supplementation of xanthohumol attenuate the severity of symptoms and duration of´viral infections.
Detailed description
In this placebo-controlled study, blood is taken on the first day of the study, followed by a 90-day intervention with xanthohumol or a placebo, which is taken twice daily. Blood samples will be taken on day 0, day 45 and day 90. Should the study participants develop a respiratory infection during the study, they will be asked to perform a self-test.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Dietary Supplement: XanthohumolParticipants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days |
| Placebo | Experimental | Dietary Supplement: PlaceboParticipants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- healthy
- BMI >18 kg/m² or < 28kg/m²
Key exclusion criteria (8 listed)
- food intolerances
- food allergies
- chronic inflammatory diseases
- metabolic diseases
- viral or bacterial infections within the last 3 weeks of inclusion
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| XanthohumolParticipants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days | Dietary supplement | Intervention |
| PlaceboParticipants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days | Dietary supplement | Placebo |
Primary outcome
Changes in severity and duration of viral infections
Time frame: 90 days
Changes in score of Wisconsin Upper Respiratory Symptom Survey
2 secondary outcomes
Changes in blood lipid levels
Time frame: 90 days
Changes in cognitive skills
Time frame: 90 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Apr 2025.
- Individual participant dataSharing planned: No
Related trials for Infection Viral
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
RecruitingObservational study
Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
Hepatitis D
RecruitingObservational study
VIRal Pulmonary Infections in Older AGE
Viral Pulmonary Infections
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
RecruitingPhase 3
Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease
Respiratory Syncytial Virus (RSV)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Xanthohumol in people with Infection Viral, run by University of Vienna at 1 site in Austria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ina Bergheim, Prof. Dr. (+43-1-4277-54981, ina.bergheim@univie.ac.at), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in severity and duration of viral infections (time frame: 90 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Apr 2025.